Core Viewpoint - Fosun Pharma reported a decline in revenue for the first half of the year, but a significant increase in net profit, indicating a potential shift in operational efficiency despite lower sales [1] Financial Performance - The company achieved an operating revenue of 19.514 billion yuan, a year-on-year decrease of 4.63% [1] - The net profit attributable to shareholders was 1.702 billion yuan, reflecting a year-on-year growth of 38.96% [1] Strategic Developments - Fosun Pharma's subsidiary granted Sitala rights for the development, production, and commercialization of FXS6837 and related products in a global scope excluding China (including Hong Kong, Macau, and Taiwan) [1] - As part of this licensing arrangement, Fosun Pharma or its designated affiliates can acquire shares of Sitala valued at 5 million USD at zero cost [1]